Nanospectra Biosciences, Inc.
8285 El Rio Street
15 articles with Nanospectra Biosciences, Inc.
Agreement includes board position and exclusive negotiation period for further collaborative access to AuroLase® Therapy in other non-U.S. geographies.
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 mi
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Nanospectra Biosciences Announces Four Additional Prestigious Trial Sites for Pivotal AuroLase Study
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase® pivotal study. T
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the start of a pivotal study to determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Nanospectra Biosciences Announces PNAS Publication of Initial Results of First Clinical Trial of Gold Nanoshell-Localized Photothermal Ablation of Prostate Tissue
Nanospectra Biosciences, Inc. announced publication of first in human data of the company's AuroLase® Therapy for the focal ablation of prostate tissue.
Nanospectra Biosciences Announces University of Texas Medical Branch at Galveston as Clinical Trial Site
Nanospectra Biosciences, Inc. announced the addition of University of Texas Medical Branch at Galveston as the fifth trial site in its pilot feasibility study "MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue".
Nanospectra Biosciences Recognized as a ‘Houston Innovation Success’ at Congressional Healthcare Innovations Summit
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company was the featured innovation success at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University
2/1/2019As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
Nanospectra Biosciences, Inc. today announced the appointment of Michael Brawer, M.D., as Chief Medical Officer (CMO). Dr. Brawer will assume responsibility for leading Nanospectra's overall clinical development, regulatory, and medical affairs activities, effective immediately.
Nanospectra Biosciences, Inc. today announced that two of its commercial partners, Sebacia, Inc. and LiteCure, LLC, have advanced towards commercialization and indicated plans for commercial launch in the United States in 2019.
Company Completes Critical Steps Towards Commercialization of AuroLase Therapy for Solid Tumor Ablation for Localized Prostate Cancer
Gold Nanoshells Help Visibly Heat And Destroy Cancer, University of Texas M. D. Anderson Cancer Center and Nanospectra Biosciences, Inc. Study